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The number of eye diseases treated with intravitreal injections is increasing. Obviously, an injection 
of fluid into the eye results in an increase of intraocular pressure (IOP), the main risk factor for 
glaucoma. However, the effect of these repeated IOP increases on the eye is unclear. Therefore, we 
performed a systematic review with meta‑analyses. PubMed, Embase and Clinical Trials Registries 
were searched for articles investigating the relationship between intravitreal injections (anti‑vascular 
endothelial growth factor [anti‑VEGF] or steroids) and either IOP, retinal nerve fiber layer (RNFL)‑
thickness and glaucoma. Multiple meta‑analyses were performed, combining data on intravitreal 
injection of anti‑VEGF medication and dexamethasone implants. A total of 74 articles were eligible for 
meta‑analyses. The short‑term effect of an intravitreal injection of anti‑VEGF showed a statistically 
significant increase in IOP. One day after injection of anti‑VEGF, however, IOP was significantly lower 
than baseline. The long‑term time‑intervals showed no significant difference in IOP. After intravitreal 
injection of a dexamethasone implant, IOP was significantly higher than baseline 1 month post‑
injection. RNFL‑thickness was significantly reduced 6 and 12 months post‑injection of anti‑VEGF, as 
well as at end of follow up. Caution is advised when using intravitreal medication, especially when 
treating patients with advanced glaucoma; in these cases, prophylactic IOP‑lowering medication may 
be considered.
The intravitreal administration of medication through injections has revolutionized the treatment for several 
retinal disorders. One of the first descriptions of an intravitreal injection was in 1911 when Ohm reported 
a method to inject air into the eye for retinal  tamponade1,2. Almost half a century later, Sorsby and Ungar 
treated an endophthalmitis case with intravitreal administration of  Penicillin3. Nowadays, besides antibiotics 
several types of intravitreal medications are available such as anti-vascular endothelial growth factor (anti-
VEGF; e.g.bevacizumab, ranibizumab, and aflibercept). Since the introduction of anti-VEGF in 2004, the indi-
cations of anti-VEGF for retinal disorders have been increasing  continuously4–6. Choroidal neovascularization 
is a leading cause of vision loss and can occur in a variety of retinopathies [e.g. diabetic retinopathy, age-related 
macular degeneration (AMD), and retinal vein  occlusion]7,8. Currently approximately 196 million people suffer 
worldwide from AMD, an estimated 16.4 million suffer from some form of retinal vein occlusion, and 93 million 
people from diabetic  retinopathy9–11. As a result of both population growth and increased lifespan globally, these 
retinopathies are only expected to become even more prevalent. For example, it is estimated that the number of 
people suffering from AMD will have risen to 288 million by  204010. The process of angiogenesis associated with 
these conditions is heavily mediated by  VEGF12. Blocking the actions of VEGF has shown to be an effective way 
of blocking neovascularization, substantially limiting the vision loss associated with these  retinopathies13. As 
a result routine injection of anti-VEGF has been implemented on an immense scale. More recently intravitreal 
steroids (e.g. dexamethasone implants) have also been introduced.
In general, these injections are considered relatively safe, nevertheless, long-term use of the injections can 
increase the chance of ocular  complications14,15. Obviously, if a fluid is injected into the eye the intraocular pres-
sure (IOP) should increase. Therefore immediately after the administration of an intravitreal injection, acute 
fluctuations of the IOP will be present; which are related to the procedure and usually last a maximum of a few 
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 hours14,15. Recently however, several studies have reported that the administration of multiple intravitreal injec-
tions with anti-VEGF is associated with an increased risk for sustained IOP elevation, especially in patients with 
pre-existing  glaucoma16. An increase in IOP is a major risk factor for thinning of the retinal nerve fiber layer 
(RNFL)17. Chronic suppression of VEGF may cause harmful downstream effects on the RNFL. Furthermore, 
research has shown that the post-injection IOP fluctuations can also be damaging to the  RNFL18. Steroids are 
also notorious for their steroid-induced increase in  IOP19.
Although a lot of research has been done on this topic, the results are not consistent. It is clearly stated in 
multiple research what the short-term effects are; yet the long-term results have not been definitive 20. A recently 
published report on the effect of anti-VEGF on IOP and glaucoma has shown that already much research has 
been done on this topic, nonetheless the results have not been concisely quantified in a meta-analysis20.
Therefore, we performed a systematic review and meta-analyses to address the conflicting results regarding 
the short- and long-term effect of intravitreal injections on IOP, RNFL-thickness, and glaucoma. Using data 
from both observational and interventional studies, we calculated the pooled effect size for anti-VEGF and 
dexamethasone both for short- and long-term outcomes. Finally, we reported the current level of evidence for a 
potentially negative effect of intravitreal injections on IOP, RNFL-thickness, and glaucoma.
Methods
This systematic review was performed according to the Preferred Reporting Items for Systematic review 
and Meta-Analyses (PRISMA) and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 
 guidelines21,22.
Eligibility criteria for considering studies for this review. We only included observational or inter-
ventional quantitative studies, which reported on the relationship between intravitreal injection of anti-VEGF 
(bevacizumab, ranibizumab, and aflibercept) or steroids (dexamethasone implant) vs. either IOP, RNFL-
thickness, or glaucoma. With the goal of maximizing generalizability we did not exclude studies based on the 
indication(s) for treatment. In contrast to the eligibility criteria for IOP, the studies which reported mean RNFL-
thickness for a patient population which received multiple types of injections, were also included. Unfortunately, 
our literature search yielded no studies in which glaucoma served as the outcome.
Search methods for identifying studies. Two researchers (VAdeV and FLB) independently conducted 
literature searches in the PubMed, and Embase databases and Clinical Trial Registries (clinicaltrialsregister.
eu; clinicaltrials.gov) on August  7th23,24, 2019. The following search strategy was performed to search for arti-
cles investigating the relationship between intravitreal injections and IOP: “(intravitreal bevacizumab AND 
intraocular pressure) OR (intravitreal ranibizumab AND intraocular pressure) OR (intravitreal aflibercept AND 
intraocular pressure) OR (intravitreal dexamethasone AND intraocular pressure)”. Similarly, a search was per-
formed for studies investigating intravitreal injection and RNFL-thickness: “(intravitreal bevacizumab AND 
retinal nerve fiber layer) OR (intravitreal ranibizumab AND retinal nerve fiber layer) OR (intravitreal aflibercept 
AND retinal nerve fiber layer) OR (intravitreal dexamethasone AND retinal nerve fiber layer) OR (intravitreal 
AND retinal fiber layer)”. Finally, we performed a search for studies on the relationship between intravitreal 
injections and glaucoma: “(intravitreal injections) AND (glaucoma) NOT (neovascular glaucoma) NOT (sur-
gery)”. We only included studies with an available abstract, with human participants, and studies of which a full 
text was available in either English or German.
Study selection. From the initial search, titles and abstracts were scanned independently by two authors 
for eligible articles, in which the relationship between intravitreal injection and IOP or RNFL-thickness, respec-
tively, was investigated, without any other restricting selection criteria. Next, the full text of the eligible studies 
was used to select additional studies from the reference lists in a similar fashion. Finally, the results were com-
pared, and discrepancies were discussed. If the two researchers could not reach consensus, a third researcher 
was involved to clarify.
Data collection and risk of bias assessment. For each study we extracted the name of the authors, title, 
year of publication, study design, sample size, method of assessing outcome(s), indication for injection, injected 
medication (exposure), means with corresponding standard deviations for both a post-injection and control 
group, and type of control (i.e., the same eye pre-injection, the contralateral eye, or healthy volunteers). To 
assess the methodological quality and risk of bias within individual studies the Newcastle–Ottawa Scale (NOS) 
for assessing the quality of comparative non-randomized studies was used. For randomized studies we used the 
Cochrane risk-of-bias Tool for Randomized Trials (RoB2). Two authors assessed the retrieved studies indepen-
dently, after which any discrepancies were discussed. Where these two authors could not reach consensus, a 
third would give resolution. The certainty of evidence was determined by using the Grading of Recommenda-
tions, Assessment, Development, and Evaluation (GRADE) approach.
Data synthesis and analysis. As the number of studies reporting an effect estimate of intravitreal injec-
tions on glaucoma was zero, a meta-analysis could not be performed. Therefore, we focused on the most impor-
tant quantitative measures for treatment (IOP) and diagnosis (RNFL) of glaucoma. The primary outcome in 
the IOP-analyses and RNFL-thickness analyses was the difference in IOP and RNFL-thickness, respectively, 
between pre- (baseline) and post-injection (follow-up). For both primary outcomes we performed meta-analy-
ses to calculate the weighted mean difference (WMD) with corresponding 95% confidence interval (CI) for each 
3
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:13248  | https://doi.org/10.1038/s41598-020-70269-7
www.nature.com/scientificreports/
of the four intravitreal medications (e.g. bevacizumab, ranibizumab, aflibercept, or dexamethasone implant), 
and for all anti-VEGF medications combined, for all time intervals with at least 3 studies reporting IOP or RNFL. 
The specified time-intervals were: within 1 min after injection, 5 min after injection, 10 min, 15 min, 30 min, 
1 h, 1 day, 1 week, 2 weeks, 1 month, 2 month, 3 months, 4 months, 6 months, and 12 months after injection. We 
also performed a meta-analysis for the RNFL-thickness at the end of follow-up. If a meaningful meta-analysis 
could not be conducted for one of the intravitreal medications, for example, in case of an insufficient number of 
studies, we reported the individual results of these studies. The threshold for statistical significance was identi-
fied as a P value of 0.05 or less.
Heterogeneity of the meta-analyses was measured by calculating  I225. In case of low heterogeneity  (I2 < 50%), 
a fixed effects model was used in our meta-analyses. In case of high heterogeneity  (I2 > 50%) a random effects 
model was used.
Statistical analyses were performed using Review Manager 5.3 for Windows (Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014) and SPSS (IBM, Statistical Package for Social Sciences, 
Release 24.0.0.1).
Results
Across all performed searches a total of 4,024 articles were found, of which 77 were included in our review and 
74 were included in our meta-analyses.
The literature search for studies investigating IOP yielded a total of 70 eligible  articles26–95, of which 68 were 
eligible for meta-analyses (Fig. 1; Supplementary Table S1). The literature search for studies investigating RNFL-
thickness yielded a total of 11 eligible  articles58,86,96–103, of which 9 were eligible for meta-analyses (Fig. 1; Sup-
plementary Table S1). Overall, the methodological quality within individual studies was good (Supplementary 
Tables S2, S3).
The literature search for studies investigating the relationship between intravitreal injections and glaucoma 
yielded 260 articles from Pubmed and 448 articles from Embase. After scanning the articles and reading the full 
texts of potentially suitable articles, no studies were deemed eligible for inclusion.
Intravitreal injection of anti‑VEGF and IOP. For the meta-analysis of bevacizumab, a total of 27 stud-
ies (1,488 eyes), investigating IOP after intravitreal injection were identified for meta-analysis (Supplementary 
Table S1; Supplementary Fig. S1). The WMD [95% CI] for IOP (in mmHg) was 23.88 [22.41, 25.34] immediately 
after injection and declined to 2.48 [1.24, 3.72] 30 min post-injection (Supplementary Fig. S2). On the day after 
injection the WMD of IOP (in mmHg) was significantly lower (− 1.19 [− 2.00, − 0.37]) compared to baseline, 
Figure 1.  Flow diagram (according to PRISMA) showing the selection process for inclusion of studies from 
our searches on the relationship between intravitreal injection and IOP or RNFL-thickness. IOP intraocular 
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and no significant difference in IOP was found for any later time-interval. For ranibizumab, 14 studies (1,057 
eyes) were included for the meta-analysis, which reported on IOP after intravitreal injection (Supplementary 
Table S1, Supplementary Fig. S3). The WMD [95% CI] in IOP (in mmHg) was 25.95 [21.46, 30.45] immediately 
after injection and declined to 2.61 [1.76, 3.46] 30 min post-injection (Supplementary Fig. S4). Although the IOP 
showed a downwards trend on the day after injection with an WMD of − 0.17 [− 0.59, 0.26], this difference was 
not statistically significant (P = 0.44). The WMD of IOP was also not significantly different than baseline after the 
later time-intervals. For aflibercept, 4 studies (133 eyes) were found (Supplementary Table S1). The minimum 
threshold of 3 studies or more was not reached for a single time-interval. Therefore, a meaningful meta-analysis 
could not be performed on the relationship between aflibercept intravitreal injections and post-injection IOP. 
Studies reporting on aflibercept were, however, included in our meta-analysis on IOP after intravitreal injection 
of any anti-VEGF (i.e., all anti-VEGF medications combined).
A total of 46 articles (2,872 eyes) were included for the meta-analyses on the relationship between the intra-
vitreal injection of any anti-VEGF and post-injection IOP. The meta-analyses were performed for 15 different 
time intervals, ranging from the IOP immediately after injection (< 1 min) to the IOP after 12 months (Fig. 2; 
Supplementary Fig. S5). On the day of injection, we found for all included time-intervals a statistically significant 
increase in IOP. The WMD [95% CI] for IOP (in mmHg) was 23.41 [18.12, 28.70] immediately after injection 
and declined to 2.51 [1.87, 3.15] after 30 min. On the day after injection of anti-VEGF, however, the WMD [95% 
CI] for IOP (in mmHg) was significantly lower at − 0.63 [− 1.04, − 0.22]. IOP normalized after one week to 0.12 
[− 1.05, 1.29] and no significant difference in IOP compared to baseline was found for all subsequent intervals. 
Heterogeneity  (I2) was higher than 50% for all our short-term time-intervals up to and including IOP at 2 weeks 
post-injection. For IOP at 1-month post-injection and all later time-intervals (2, 3, 4, 6, and 12 months post-
injection) heterogeneity was below 50%.
Intravitreal injection of a dexamethasone implant and IOP. A total of 26 articles (1,744 eyes) on 
intravitreal injection of a dexamethasone implant and IOP were identified for meta-analysis (Fig. 2; Supple-
mentary Fig. S6). None of the identified studies reported on the change in IOP within 1 day after injection. No 
statistically significant difference was found between the IOP 1 day after injection and IOP at baseline (P = 0.70). 
IOP was significantly increased at all later time-intervals, except of at end of follow-up (12 months: P = 0.11). The 
WMD [95% CI] for IOP (in mmHg) was 0.80 [0.47, 1.14] at 1 week, 2.04 [1.31, 2.78] at 1 month, 2.49 [1.51, 3.46] 
at 2 months, 1.65 [1.22, 2.07] at 3 months, 1.11 [0.53, 1.70] at 4 months, and 0.91 [0.49, 1.33] at 6 months after 
intravitreal injection. Heterogeneity  (I2) was higher than 50% for all specified time-intervals, except for 1 week 
 (I2 = 0%) and 12 months post-injection  (I2 = 38%).
Intravitreal injection of anti‑VEGF or dexamethasone implant and RNFL‑thickness. Our lit-
erature search yielded 11 articles reporting on the relationship between anti-VEGF or dexamethasone implants 
and the average RNFL-thickness.
Five studies reported on RNFL-thickness at end of follow-up and were eligible for meta-analyses (Sup-
plementary Table S1). Mean ± standard deviation follow-up for studies included in the meta-analysis was 
Figure 2.  Weighted mean difference in IOP during follow-up after intravitreal injection of anti-VEGF and 
Dexamethasone implant. IOP intraocular pressure, VEGF vascular endothelial growth factor.
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23.40 ± 9.08 months. A total of 385 eyes were included in this meta-analysis. The WMD [95% CI] was − 2.67 
[− 3.57, − 1.78] µm (Fig. 3).
Six studies investigated RNFL-thickness at a specific point in time during follow-up. Bulut et al. found that 
6 months after dexamethasone implant the average RNFL-thickness had been reduced from 104.1 ± 11.1 µm to 
101.1 ± 10.4 µm (P < 0.001)37. Four of the studies (124 eyes) were included in our meta-analysis for anti-VEGF. 
The WMD [95% CI] for RNFL-thickness (in µm) at 3, 6, and 12 months was − 3.45 [− 7.13, 0.24], − 2.53 [− 5.09, 
0.03], and − 3.34 [− 5.95, − 0.73], respectively. RNFL-thickness was only significantly reduced at 12 months 
(P = 0.01; Fig. 3). Heterogeneity  (I2) was low between 0 and 19% for the specified time-intervals.
Risk of bias and overall certainty of evidence. The mean ± standard deviation Newcastle–Ottawa sum 
score for all observational studies included in this review was 8.65 ± 0.66 (Supplementary Table S2). For obser-
vational studies investigating IOP and RNFL-thickness the score was 8.64 ± 0.69 and 8.77 ± 0.43, respectively. 
The Cochrane risk-of-bias for randomized studies tool showed a high risk of bias for all interventional studies 
(Supplementary Table S3). As per the GRADE approach, the evidence of this meta-analysis warrants a low level 
of certainty (Supplementary Table S4).
Discussion
Summary of findings. In this study we summarized the available scientific literature on the effect of anti-
VEGF intravitreal injections and dexamethasone implant injections on the most important quantifiable meas-
ures for glaucoma (IOP and RNFL-thickness). After intravitreal injection of anti-VEGF, the IOP was signifi-
cantly increased for all measured time-intervals on the day of injection. IOP was slightly decreased on the day 
after injection. IOP did not differ significantly from baseline during any later follow-up measurements. After the 
Figure 3.  Meta‐analyses for the association of anti-VEGF and RNFL-thickness. Black diamonds indicate the 
overall WMD. The size of the gray box is inversely proportional to the variance. Horizontal lines indicate 95% 
CI. The vertical line in each panel shows the value for no effect (WMD = 0). RNFL retinal nerve fiber layer, 
WMD weighted mean difference, I 3 months post-injection, II 6 months, III 12 months, IV at end of follow-up.
6
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:13248  | https://doi.org/10.1038/s41598-020-70269-7
www.nature.com/scientificreports/
injection of a dexamethasone implant, IOP was increased for all long-term time-intervals until the 12-month 
endpoint.
Substantially less evidence was available on the relationship between intravitreal injections and RNFL-thick-
ness. For our meta-analysis pooling all anti-VEGF results at end of follow-up we found a significant reduction 
in RNFL-thickness at 12 months and at end of follow-up. However, with a RNFL-thickness reduction of only 2 
to 3 µm after an average follow-up of 23 months, the clinical relevance of these findings is unclear.
Relationship with literature. As mentioned before, the IOP showed a slight decrease the day immediately 
after injection, according to research this is most likely due to ciliary body inflammation as a result of the sharp 
IOP rise after the intravitreal  injection76.
Although the literature on alternative corticosteroids is still sparse, some studies have shown that triamci-
nolone acetonide intravitreal injections result in similar rates of ocular hypertension compared to dexametha-
sone  implant104,105. Similarly Vaz-Pereira et al. could not find a significant difference in IOP after switching from 
dexamethasone to fluocinolone  acetonide106. More research will have to be done in order to be able to more 
clearly distinguish the pros and cons of the different corticosteroid injections available.
There are several known risk factors for glaucoma such as older age, a family history of glaucoma, and 
 myopia107–109. It has been suggested that the recurrent transient rising IOP after intravitreal injection could also 
be correlated with an increased incidence of glaucoma. A recent report by the American Academy of Ophthal-
mology reviews this effect and found mixed results, with 6 studies reporting an incidence between 4 and 15% of 
sustained IOP elevation and 7 studies reporting no long-term change in  IOP20. By performing meta-analyses, 
we have come to a more definitive answer: IOP normalizes within days after intravitreal injection of anti-VEGF, 
but after injection of a dexamethasone implant IOP remains elevated. Recurrent injections of anti-VEGF reduce 
RNFL-thickness; however, this reduction does not appear to be clinically relevant. Moreover, the studies used 
different optical coherence tomography (OCT)-devices of which the results may not be  interchangeable110. 
However, within the studies baseline and follow-up RNFL were measured with the same OCT-device.
Several studies have shown that the post-intravitreal injection rise in IOP can be prevented by using glaucoma 
medication such as brimonidine/timolol and acetazolamide. For example, administering patients 500 mg oral 
acetazolamide 60–90 min before injection resulted in a significant reduction in IOP at 30 min post-injection 
of 5.5 mmHg74. Another study evaluated the effects of oral acetazolamide and topical brimonidine tartrate. In 
this study the IOP of pretreated eyes returned to baseline within 10 min, whereas eyes that were not pretreated 
remained elevated at 30 min post-injection111. A fixed combination of brimonidine/timolol twice a day on the day 
before and the day of the intravitreal injection was also an effective prophylaxis to reduce the acute IOP-spikes of 
the post-injection  period112. At 5 min post-injection the mean IOP was significantly higher in the control group 
when compared with the pretreatment group. The mean IOP normalized at 15 min for the pretreatment group, 
whereas this was only the case after 30 min for the control  group112. Additionally, several studies have shown 
that prophylactic anterior chamber paracentesis is a safe and effective option for preventing IOP spikes after an 
intravitreal  injection87,113,114. Most notably, Enders et al. found a significant RNFL-loss in patients who had not 
undergone anterior chamber paracentesis prior to their intravitreal injections, but could not find a significant 
reduction in RNFL-thickness in those who  did115. We can therefore conclude that there are several effective 
options for IOP prophylaxis. It has been suggested that the acute IOP changing after intravitreal injections 
could be causing perfusion-related injury to ocular structures, potentially resulting in glaucomatous damage 
to the macula and optic  nerve116. This mechanism may be similar to the IOP-increase seen during intraocular 
surgery, which may result in a sudden loss of vision, also known as “wipe-out”117,118. During cataract surgery, 
which takes around 7 min, IOP increases up to 30–40 mmHg several times. This is one of the main reasons that 
ophthalmologists are very reluctant to operate on eyes with advanced glaucoma (visual field < 10°). A similar 
rise in IOP is seen after intravitreal injections, which therefore might have a similar effect of visual field loss. 
Scientific evidence to support this hypothesis is nonetheless  lacking119.
IOP monitoring and prophylaxis should therefore be considered before giving intravitreal injections, espe-
cially in patients with advanced glaucoma or patients at risk for glaucoma who will receive a dexamethasone 
implant.
Strengths and weakness. The strengths of this study include a high quality and number of reviewed 
studies. By comparing the post-injection IOP or RNFL-thickness with the pre-injection IOP or RNFL-thickness 
of the same eye, the chance of confounding factors influencing the outcome was minimalized. Furthermore, we 
performed a large amount of meta-analyses to combine all available evidence in a concise and clear manner. By 
looking at both IOP and RNFL-thickness, we attempted to establish both the development of IOP over time after 
an intravitreal injection, and the long-term effect of these IOP elevations. Finally, by including studies regardless 
of the indication for an intravitreal injection, our results are generalizable, and its implications can be applied to 
a large number of patients. For example, most patients treated with anti-VEGF are treated with different types of 
anti-VEGF during their life depending on the effect of the anti-VEGF on the indicated disease.
Nevertheless, some limitations have to be considered. Most notably, the heterogeneity was high for some of 
our IOP related meta-analyses and especially for our short-term time-intervals. This is possibly due to the volatile 
and unpredictable nature of the immediate IOP rise after injection. Alternatively, the variability in IOP-measuring 
methods, frequency of injection, and the usage of IOP-lowering agents could have an effect on the heterogeneity 
of this review. During a previous study a greater IOP elevation post-injection was seen, if the interval between 
injections was less than 8 weeks and the frequency of injections in eyes with a sustained IOP elevation was 
significantly higher than in eyes without sustained IOP  elevation120. Another factor that could contribute to 
the heterogeneity is the type of anti-VEGF medication used. We included studies evaluating the effect of either 
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bevacizumab, ranibizumab or aflibercept. According to previous research, a significant IOP increase can be found 
when using bevacizumab and ranibizumab and not with  aflibercept121–124. We did not exclude studies based on 
the use of anesthetic method for the intravitreal injection. One study has shown that decompressing the eye 
with lidocaine soaked cotton swabs applied with moderate pressure, compared to lidocaine gel applied without 
pressure, reduces the post-injection IOP  spike52. A last factor that could explain the heterogeneity is that some 
studies did not exclude patients with a history of glaucoma. Several studies have shown a relationship between 
a history of glaucoma and higher IOP elevations after  injection122,125,126.
Secondly, this systematic review is based primarily on observational studies, with only a view RCT’s included. 
Some unknown confounding or predisposing factors may have been missed; a threat inherent to the observa-
tional nature of these studies.
Thirdly, although the injection of a dexamethasone implant did seem to result in a sustained rise in IOP, we 
were not able to evaluate the long-term effects of this elevation on RNFL-thickness, due to a lack of available 
literature on this topic.
Conclusion and recommendation. IOP rises sharply immediately after intravitreal injection of anti-
VEGF. This appears to be a transient rise, with the IOP normalizing within 1–7 days. However, after the injec-
tion of a dexamethasone implant, IOP will remain elevated for several months, before finally normalizing 1-year 
post-injection. Caution is therefore advised with the use of this form of intravitreal medication. Very little evi-
dence is available on the long-term effects on RNFL-thickness. Some diminishment in RNFL-thickness seems 
to occur after intravitreal injection of anti-VEGF, but the clinical relevance of this finding remains unclear. In 
particular, the relationship between the intravitreal injection of a dexamethasone implant and RNFL-thickness 
requires further research. The current results suggest that the effect of intravitreal injection on glaucoma is not of 
clinical significance, however, caution should be taken when treating patients with advanced glaucoma. In these 
cases, prophylactic IOP-lowering medication or anterior chamber paracentesis should be considered. Future 
studies with visual field progression or glaucoma as an outcome itself are warranted.
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